Tarsus Pharmaceuticals (TARS) Gross Profit (2021 - 2026)

Tarsus Pharmaceuticals' Gross Profit history runs 6 years deep, the most recent figure standing at $152.7 million for Q1 2026.

• In Q1 2026, Gross Profit rose 108.77% year-over-year to $152.7 million; the TTM figure through Mar 2026 stood at $500.2 million (up 130.2% YoY), while the FY2025 annual figure was $420.7 million, up 147.27% from the prior year.
• Gross Profit was $152.7 million for Q1 2026 at Tarsus Pharmaceuticals, up from $140.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $152.7 million in Q1 2026 to a low of $506000.0 in Q1 2022.
• Historically, Gross Profit has averaged $52.3 million across 5 years, with a median of $37.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Gross Profit slumped 98.43% in 2022, then jumped 2903.75% in 2024.
• A 5-year view of Gross Profit shows it stood at $10.6 million in 2022, then climbed by 12.36% to $11.9 million in 2023, then soared by 418.4% to $61.5 million in 2024, then jumped by 128.91% to $140.7 million in 2025, then rose by 8.47% to $152.7 million in 2026.
• The last three Gross Profit figures came in at $152.7 million (Q1 2026), $140.7 million (Q4 2025), and $110.4 million (Q3 2025), per Business Quant data.